Viromed Medical Valuation Multiples

Viromed Medical Overview

About Viromed Medical

Viromed Medical AG is a medical technology company. It focuses on using cold plasma technology to develop medical solutions that protect people from viruses, bacteria, and multi-resistant germs. Viromed's product offerings include ViroCAP, a medical device based on cold plasma technology for treating wounds; ViroCAP derma-podo, a medical device that uses cold atmospheric plasma therapy for skin and foot care; and a Raumluftentkeimer. The company covers the entire value chain from research and development to production, logistics, marketing, and sales of its products.

Founded

N/A

HQ

Employees

N/A

Website

viromed-medical-ag.de

Sectors

Medical Devices

Financials (LTM)

Revenue: $21M

EBITDA: $3M

EV

$95M

Valuation Multiples

Multiples.vc

Start free trial

Viromed Medical Financials

Viromed Medical reported last 12-month revenue of $21M and EBITDA of $3M.

In the same LTM period, Viromed Medical generated $3M in EBITDA and $1M in net income.

Viromed Medical P&L

In the most recent fiscal year, Viromed Medical reported revenue of — and net income of —.

Viromed Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX

Viromed Medical Stock Performance

Viromed Medical has current market cap of $95M, and enterprise value of $95M.

Viromed Medical Valuation Multiples

Viromed Medical trades at 4.5x EV/Revenue multiple, and 37.1x EV/EBITDA.

Viromed Medical Financial Valuation Multiples

As of March 7, 2026, Viromed Medical has market cap of $95M and EV of $95M.

Equity research analysts estimate Viromed Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Viromed Medical has a P/E ratio of 68.6x.

Viromed Medical Margins & Growth Rates

Viromed Medical's revenue in the last 12 month grew by 245%.

Viromed Medical's rule of 40 is 258% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Viromed Medical's rule of X is 626% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Viromed Medical Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Viromed Medical M&A Activity

Viromed Medical acquired XXX companies to date.

Last acquisition by Viromed Medical was on XXXXXXXX, XXXXX. Viromed Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Viromed Medical Investment Activity

Viromed Medical invested in XXX companies to date.

Viromed Medical made its latest investment on XXXXXXXX, XXXXX. Viromed Medical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).